# OnCo record durvalumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/durvalumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "durvalumab" ;
  schema:name "Durvalumab"@en ;
  schema:description "A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers."@en ;
  schema:url <https://onco.cc/drugs/durvalumab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Durvalumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q19904005> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Durvalumab>, <https://www.nice.org.uk/guidance/ta798>, <https://www.nice.org.uk/guidance/ta1030>, <https://www.nice.org.uk/guidance/ta1041>, <https://www.nice.org.uk/guidance/ta1099> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-L1)" ;
  schema:alternateName "Imfinzi" ;
  onco:approval "US 2017: Locally advanced or metastatic urothelial carcinoma after platinum (accelerated; indication withdrawn 2021)", "US 2018: Unresectable stage III NSCLC after chemoradiation", "US 2022: Locally advanced or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (TOPAZ-1)", "UK 2024: Locally advanced, unresectable or metastatic biliary tract cancer with gemcitabine and cisplatin; NICE TA944 recommended 10 January 2024 with a commercial arrangement", "US 2026: High-risk NMIBC with BCG", "England (NICE) 2022: Locally advanced unresectable non-small-cell lung cancer with PD-L1 on 1 percent or more of cells that has not progressed after concurrent platinum-based chemoradiation", "England (NICE) 2025: Untreated extensive-stage small-cell lung cancer, with etoposide and either carboplatin or cisplatin", "England (NICE) 2025: Resectable non-small-cell lung cancer (4 cm or more, or node positive) without an EGFR mutation or ALK rearrangement, neoadjuvant with platinum chemotherapy then adjuvant alone", "England (NICE) 2025: Limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy" ;
  onco:acceleratedApproval "US 2017-05-01: Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-advanced/>, <https://onco.cc/cancers/hcc-intermediate/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/resectable-nsclc/>, <https://onco.cc/cancers/stage-iii-unresectable-nsclc/>, <https://onco.cc/cancers/limited-stage-sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>, <https://onco.cc/cancers/tnbc-early/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/tropion-breast05/>, <https://onco.cc/trials/nct05170204/>, <https://onco.cc/trials/nct07005128/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/trials/nct05043090/>, <https://onco.cc/trials/nct07361497/>, <https://onco.cc/trials/nct06746116/>, <https://onco.cc/trials/nct03164616/>, <https://onco.cc/trials/nct05883644/>, <https://onco.cc/trials/nct03847428/>, <https://onco.cc/trials/nct05557838/>, <https://onco.cc/trials/nct07195695/>, <https://onco.cc/trials/nct07081633/>, <https://onco.cc/trials/nct06780137/>, <https://onco.cc/trials/nct03228667/>, <https://onco.cc/trials/nct05925530/>, <https://onco.cc/trials/nct04745689/>, <https://onco.cc/trials/nct06606847/>, <https://onco.cc/trials/nct04644289/>, <https://onco.cc/trials/nct06463665/>, <https://onco.cc/trials/nct04068610/>, <https://onco.cc/trials/nct03775486/>, <https://onco.cc/trials/nct05061550/>, <https://onco.cc/trials/nct05063565/>, <https://onco.cc/trials/nct05733598/>, <https://onco.cc/trials/nct07459634/>, <https://onco.cc/trials/nct06040099/>, <https://onco.cc/trials/nct07174583/>, <https://onco.cc/trials/nct05061134/>, <https://onco.cc/trials/nct03944772/>, <https://onco.cc/trials/nct02519348/>, <https://onco.cc/trials/nct05742607/>, <https://onco.cc/trials/nct07720284/>, <https://onco.cc/trials/nct03706690/>, <https://onco.cc/trials/nct07710885/>, <https://onco.cc/trials/nct05771480/>, <https://onco.cc/trials/nct03682068/>, <https://onco.cc/trials/nct05498155/>, <https://onco.cc/trials/nct06008093/>, <https://onco.cc/trials/nct05687266/>, <https://onco.cc/trials/nct04538742/>, <https://onco.cc/trials/nct06467357/>, <https://onco.cc/trials/nct02671435/>, <https://onco.cc/trials/nct02516241/>, <https://onco.cc/trials/nct05943106/>, <https://onco.cc/trials/nct06667908/>, <https://onco.cc/trials/nct02453282/>, <https://onco.cc/trials/nct06960577/>, <https://onco.cc/trials/nct03837899/>, <https://onco.cc/trials/nct02542293/>, <https://onco.cc/trials/nct06112379/>, <https://onco.cc/trials/nct03833154/>, <https://onco.cc/trials/nct04999969/>, <https://onco.cc/trials/nct04379596/>, <https://onco.cc/trials/nct03003962/>, <https://onco.cc/trials/nct05374603/>, <https://onco.cc/trials/nct06992609/>, <https://onco.cc/trials/nct03459846/>, <https://onco.cc/trials/nct03742102/>, <https://onco.cc/trials/nct07221253/>, <https://onco.cc/trials/nct06591520/>, <https://onco.cc/trials/nct04960709/>, <https://onco.cc/trials/nct05941897/>, <https://onco.cc/trials/nct04550260/>, <https://onco.cc/trials/nct06890598/>, <https://onco.cc/trials/phoenix/>, <https://onco.cc/trials/diamond/>, <https://onco.cc/trials/tropion-breast03/>, <https://onco.cc/trials/pacific/>, <https://onco.cc/trials/pacific-2/>, <https://onco.cc/trials/caspian/>, <https://onco.cc/trials/adriatic/>, <https://onco.cc/trials/gemstone-301/> ;
  onco:people <https://onco.cc/people/lajos-pusztai/> .